

## Confirmed Speakers

### Keynote Speakers

#### Cutting-Edge Mass Spectrometry Methods for the Multi-Level Structural Characterization of mAbs and ADCs (KL03)



Dr Alain BECK  
(PIERRE FABRE, St Julien-en-Genevois, France)

#### Allosteric Mechanisms of Signal Transduction Investigated with Pentameric Ligand Gated Ion Channels: Consequences for Drug Design (KL01)



Prof. Jean-Pierre CHANGEUX  
(COLLÈGE DE FRANCE & INSTITUT PASTEUR, Paris, France)

#### FBLD and Biophysics: Better Together (KL02)



Dr Dan ERLANSON  
(CARMOT THERAPEUTICS, San Francisco, United States)

### Session 1: Biophysical Techniques for the Study of Integral Membrane Proteins

#### Method for Rapid Optimization of Recombinant GPCR Protein Expression and Stability Using Virus-Like Particles (OC02)



Dr Kathleen AERTGEERTS  
(DART NEUROSCIENCE, San Diego, United States)

#### Enabling Biophysics on Membrane Proteins Targets : Example of a Human Nucleoside Transporter (PL02)



Dr Nicolas BOCQUET  
(LEADXP AG, Villigen, Switzerland)

#### Biophysical Analysis to Aid and Complement Structure Based Drug Design for GPCRS (OC01)



Dr Carmen DREGGER  
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)

#### Use of Mini-G Proteins to Study the Activate State of G Protein-Coupled Receptors (PL01)



Dr Chris TATE  
(MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge, United Kingdom)

### Session 2: Recent Advances in NMR

#### Study of Protein Folding and Ligand Binding by Pressure Jump NMR (PL03)



Prof. Ad BAX  
(NATIONAL INSTITUTES OF HEALTH, Bethesda, United States)

## Confirmed Speakers

### New NMR Tools for Drug Discovery : From Validation to Structure Determination (PL04)



Dr Alvar GOSSERT  
(ETH ZÜRICH, Zürich, Switzerland)

### NMR as a Powerful Tool for Identifying Natural Compounds Able to Interfere with ELAV-mRNA Complexes (OC03)



Dr Francesca VASILE  
(UNIVERSITY OF MILANO, Milano, Italy)

## Session 3: Hot Topics

### Precision of Biophysical Techniques that Determine Protein? Compound Dissociation Constants, Lessons from our Database of over 700 Ligand Kds Determined by ITC, FTSA(DSF), SPR, and SFA (OC05)



Prof. Daumantas MATULIS  
(INSTITUTE OF BIOTECHNOLOGY, Vilnius, Lithuania)

### Biophysical Assays to Answer Evolving Questions in Drug Discovery (OC04)



Dr Derrick MEINHOLD  
(GLAXOSMITHKLINE, Conshohocken, United States)

## Session 4: Recent Advances in FBDD

### Fragment Screening against DC-SIGN Identifies Multiple Druggable Secondary Sites (OC07)



Mr Hannes BAUKMANN  
(MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES, Potsdam-Golm, Germany)

### A New Heuristic to Predict 3D Ligand Bound Conformation by Mining PDB Subpockets (OC08)



Mr Olivier BEQUIGNON  
(JANSSEN R&D, Val de Reuil Cedex, France)

### XCHEM: A High Throughput in Crystallo Fragment Screening Platform (OC06)



Dr Alexandre DIAS  
(DIAMOND LIGHT SOURCE LTD, Didcot, Oxon, United Kingdom)

### Fragment Based Lead Generation – What Drives Success? (PL05)



Dr Jenny SANDMARK  
(ASTRAZENECA, Gothenburg, Sweden)

### Navigating Biophysical Space in Search of Medicines (PL06)

## Confirmed Speakers



Dr Glyn WILLIAMS  
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

### Session 5: Detecting Allosteric Effectors

#### Large Scale Protein Conformational Motions : From Fundamental Biophysics to Functional Dynamics (PL07)



Prof. Martin BLACKLEDGE  
(IBS - INSTITUT DE BIOLOGIE STRUCTURALE, Grenoble, France)

#### Analysis of Allosteric Modulators with Kinetic Fret (OC11)



Dr Martin REDHEAD  
(UCB, Slough, United Kingdom)

#### Surface Plasmon Resonance Based Method to Discriminate Direct Competition and Allosteric Effects in Ternary Systems (OC10)



Dr Armin RUF  
(F. HOFFMANN - LA ROCHE, Basel, Switzerland)

#### Spectroscopic Adventures in Orthosteric and Allosteric Inhibition (PL08)



Dr Richard TAYLOR  
(UCB, Slough, United Kingdom)

#### Identifying Allosteric Modifiers of K-RAS Using Second Harmonic Generation (OC09)



Dr Elizabeth VO  
(UCSF, San Francisco, United States)

### Session 6: IDPs and the Dark Proteome

#### Finding Small-Molecules Inhibitors of the Interaction between the Intrinsically Disordered Androgen Receptor N-Terminal Domain and its Globular Partner RAP74 C-Terminal Domain (OC12)



Mrs Marta FRIGOLÉ-VIVAS  
(INSTITUTE FOR RESEARCH IN BIOMEDICINE (IRB BARCELONA), Barcelona, Spain)

#### Systematic Development of Small Molecules Against A $\beta$ Aggregation (PL10)



Prof. Michele VENDRUSCOLO  
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

#### Mechanistic Insights into TSPO and IDPs through NMR (PL09)

## Confirmed Speakers

---



Prof. Markus ZWECKSTETTER  
(MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY, Göttingen, Germany)

## Session 7: Antibodies and Relatives

### Adnectin Bioconjugates for PET Imaging and Targeted Drug Conjugates (PL11)



Dr Jim BRYSON  
(BRISTOL-MYERS-SQUIBB R&D, New York, United States)

### Thermal Stabilization and Conformational Trapping of Membrane Transporters by in Vitro Selected Synthetic Nanobodies (PL12)



Prof. Markus SEEGER  
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland)